Iejimalid analoga and uses thereof
The invention relates to Iejimalides having the following formula (I) in which a, b, c, d, e, f, g, h, i, j, k, l, m, n, o, p are simple or double bonds, the continuous lines representing at least one simple bond, the dotted lines representing a possible bond. A double bond can be present but it is not necessary, and provided that a continuous line is also present, or a simple bond can be present if no other line is represented; m=0-20 and n1-n18=1, 2. The bonds can be used as chemotherapeutic agents for treating cancer.
1. A compound having the structure:
wherein:
m=0-20;
R 1-14 independently represent hydrogen or alkyl;
X 1 is O;
X 2 is O;
X 3 is NHR h , wherein R h is a natural or unnatural amino acid residue bound to NH of X 3 by amide linkage, the unnatural amino acid residue being selected from the group consisting of:
A, C and D independently represent CH 2 , CHR j or C(R j ) 2 , wherein each occurrence of R j is hydrogen or alkyl; and
each B independently represents CHR 1 , wherein each R 1 is independently OR m , wherein R m is independently hydrogen or alkyl;
with the proviso that the following compounds are excluded: compounds wherein the following occur simultaneously: X 1 is O (S configuration), X 2 is O, R 1 =Me, R 2 =H, A=CHCH 3 (R configuration), R 3 =R 4 =H, R 5 =Me, R 6 =H, B is CHOMe (S configuration), C is CH 2 , R 7 =R 8 =H, R 9 =Me, R 10 =H, B is CHOMe (S configuration), R 11 =R 12 =R 13 =R 14 =H, D is CHCH 3 (S configuration), m=1, and X 3 is:
wherein Rn=TBS.
2. The compound having the structure:
3. The compound according to claim 1 , which has the structure:
4. The compound according to claim 1 , which has the structure:
5. The compound according to claim 1 , which has the structure:
6. The compound according to claim 1 , which has the structure:
7. A pharmaceutical composition comprising at least one compound according to claim 1 .